Alzheimer's Disease Clinical Trials Recruiting in the US
262 studies for Alzheimer's Disease are recruiting at 1,119 US sites, according to ClinicalTrials.gov data processed .
Alzheimer's disease is a progressive brain disorder that gradually affects memory, thinking and the ability to carry out daily tasks.
Recruiting now
Top Alzheimer's Disease studies by number of US sites
Showing 30 studies, most US recruiting sites first.
- Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
NCT07177352
- Phase 3
- Ages 50 to 90 years
- Sex: All
- Recruiting sites
- 68 US recruiting sites
- Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
NCT05980949
- Phase 3
- Ages 55 to 90 years
- Sex: All
- Recruiting sites
- 57 US recruiting sites
- A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
NCT07602582
- Phase 3
- Ages 55 years and older
- Sex: All
- Recruiting sites
- 55 US recruiting sites
- A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
NCT06585787
- Phase 3
- Ages 55 to 90 years
- Sex: All
- Recruiting sites
- 44 US recruiting sites
- Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
NCT06563895
- Phase 3
- Ages 18 to 75 years
- Sex: All
- Recruiting sites
- 40 US recruiting sites
- Recruiting sites
- 36 US recruiting sites
- Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
NCT06847321
- Phase 2
- Ages 55 to 80 years
- Sex: All
- Recruiting sites
- 36 US recruiting sites
- A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
NCT06887192
- Phase 2
- Ages 55 to 90 years
- Sex: All
- Recruiting sites
- 36 US recruiting sites
- A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
NCT07589595
- Phase 2
- Ages 55 to 85 years
- Sex: All
- Recruiting sites
- 36 US recruiting sites
- A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
NCT07033494
- Phase 2
- Ages 50 to 85 years
- Sex: All
- Recruiting sites
- 35 US recruiting sites
- Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
NCT06808984
- Phase 2
- Ages 55 to 90 years
- Sex: All
- Recruiting sites
- 32 US recruiting sites
- A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
NCT06651567
- Phase 2
- Ages 55 years and older
- Sex: All
- Recruiting sites
- 24 US recruiting sites
- A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
NCT06976216
- Phase 3
- Ages 60 to 85 years
- Sex: All
- Recruiting sites
- 24 US recruiting sites
- A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
NCT06976203
- Phase 3
- Ages 60 to 85 years
- Sex: All
- Recruiting sites
- 23 US recruiting sites
- A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
NCT07011745
- Phase 3
- Ages 55 to 90 years
- Sex: All
- Recruiting sites
- 23 US recruiting sites
- A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
NCT07011732
- Phase 3
- Ages 55 to 90 years
- Sex: All
- Recruiting sites
- 22 US recruiting sites
- A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)
NCT07633470
- Phase 4
- Ages 50 years and older
- Sex: All
- Recruiting sites
- 22 US recruiting sites
- A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
NCT06540833
- Phase 2
- Ages 55 years and older
- Sex: All
- Recruiting sites
- 19 US recruiting sites
- Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
NCT06584357
- Observational
- Ages 60 to 90 years
- Sex: All
- Accepts healthy volunteers
- Recruiting sites
- 19 US recruiting sites
- Recruiting sites
- 17 US recruiting sites
- Recruiting sites
- 14 US recruiting sites
- Late Onset Alzheimer's Disease
NCT05010603
- Observational
- Ages 55 years and older
- Sex: All
- Accepts healthy volunteers
- Recruiting sites
- 12 US recruiting sites
- A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
NCT05552157
- Phase 2/3
- Ages 18 years and older
- Sex: All
- Accepts healthy volunteers
- Recruiting sites
- 12 US recruiting sites
- A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
NCT06647498
- Phase 2/3
- Ages 18 years and older
- Sex: All
- Accepts healthy volunteers
- Recruiting sites
- 12 US recruiting sites
- A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
NCT07717411
- Phase 3
- Ages 55 to 80 years
- Sex: All
- Recruiting sites
- 12 US recruiting sites
- A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
NCT06937229
- Phase 3
- Ages 55 to 90 years
- Sex: All
- Recruiting sites
- 11 US recruiting sites
- A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease
NCT07599670
- Phase 1/2
- Ages 50 to 90 years
- Sex: All
- Recruiting sites
- 11 US recruiting sites
- A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease
NCT07688213
- Phase 2
- Ages 55 to 85 years
- Sex: All
- Recruiting sites
- 10 US recruiting sites
- Open-label Extension Study in Participants With Early Alzheimer's Disease
NCT07105709
- Phase 2
- Ages 50 to 85 years
- Sex: All
- Recruiting sites
- 9 US recruiting sites
- A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
NCT05511363
- Phase 3
- Ages 55 to 90 years
- Sex: All
- Recruiting sites
- 8 US recruiting sites
By city
Alzheimer's Disease clinical trials by city
FAQ
Common questions
What is a clinical trial?
A clinical trial is a research study in people that tests a medical, surgical or behavioral intervention, such as an investigational drug or device. Observational studies are also listed: they collect information without assigning a treatment. Read how clinical trials work.
Is there compensation for joining an Alzheimer's Disease clinical trial?
Compensation for time and travel may be available, but it varies by study and some studies offer none. The amount and schedule are reviewed by an ethics board and described in the consent form. See compensation in clinical trials.
How do I check if I'm eligible?
Each study lists age, sex and other inclusion and exclusion criteria on its ClinicalTrials.gov record. Only the study team can confirm eligibility, usually through a screening call or visit. Talk with your own doctor before joining any study.
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.